Firebrick Pharma Ltd
ASX:FRE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.05
0.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
F
|
Firebrick Pharma Ltd
ASX:FRE
|
15.8m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
519.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
274.5B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
206.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.2B USD |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Firebrick Pharma Ltd
Glance View
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Firebrick Pharma Ltd is -897.9%, which is above its 3-year median of -239 353.4%.
Over the last 3 years, Firebrick Pharma Ltd’s Net Margin has increased from -92 592.7% to -897.9%. During this period, it reached a low of -850 262.5% on Jun 30, 2023 and a high of -815.8% on Dec 31, 2024.